July 25, 2019 Modus Health earns first clinical care contract with CatoSenteret in Norway
Edmonds, Washington / Son, Norway – July 2019 Modus Health earns first clinical care contract with CatoSenteret in Norway. CatoSenteret will be working with Modus Health in the development of its Acute Care System in order to encourage increased patient mobility during their inpatient stay. Modus Health’s CEO, Teri Chou, states “Jan and his team at CatoSenteret are true innovators who are willing to work through the barriers of change for the benefit of their patients. We are excited to partner with them on this critical project.”
The goal of CatoSenteret is to improve patient health before they leave the hospital. Increased mobility plays a key role in achieving this outcome. Several publications have already shown that increased ambulation as measured by StepWatch is associated with reduced length of stay (McCullagh, 2016), risk of readmission (Fisher, 2016), and improved outcomes (Hornby, 2015). In addition, a study using many different activity monitors during inpatient care found that only StepWatch detected steps in every patient (Treacy, 2017). StepWatch has also been demonstrated to be the only accurate monitor for measuring walking in daily life (Toth, 2018). Modus Health is leveraging StepWatch’s unique accuracy and proven digital biomarkers to improve healthcare through cost-effective platforms. Modus Health’s goal is to become integrated into routine clinical care worldwide.
Jan Nordvik, CEO of the Norwegian rehabilitation center, says of the new collaboration: “The StepWatch is the most precise activity sensor that we are aware of. In clinical work this level of precision is a necessity. In addition, Teri and the Modus Health group are a great innovative team that we are certain will help us to move into a new generation of health care systems where sensor technology is essential to proving the quality of the care for our patients”.